Imunon (IMNN) Expected to Release Quarterly Earnings on Tuesday

Imunon (NASDAQ:IMNN) is anticipated to announce its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to announce earnings of ($0.8675) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 11:00 AM ET.

Imunon (NASDAQ:IMNN) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.38. On average, analysts expect Imunon to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Imunon Stock Performance

Imunon stock traded down $0.04 during midday trading on Tuesday, reaching $1.49. The stock had a trading volume of 7,395 shares, compared to its average volume of 94,854. The stock has a market capitalization of $6.24 million, a P/E ratio of -0.29 and a beta of 1.96. The firm’s fifty day simple moving average is $1.95 and its 200-day simple moving average is $2.71. Imunon has a 1-year low of $1.47 and a 1-year high of $8.19.

Institutional Investors Weigh In On Imunon

An institutional investor recently raised its stake in Imunon stock. DRW Securities LLC boosted its position in shares of Imunon, Inc. (NASDAQ:IMNN) by 6.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 58,830 shares of the company’s stock after buying an additional 3,803 shares during the period. DRW Securities LLC owned approximately 1.92% of Imunon worth $224,000 at the end of the most recent quarter. Institutional investors own 4.47% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on IMNN. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Imunon in a research report on Friday, July 17th. Maxim Group set a $10.00 target price on shares of Imunon and gave the stock a “buy” rating in a report on Friday, April 17th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $10.00.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.